Can Nitazoxanide and/or other anti‐viral medications be a solution to long COVID? Case report with a brief literature review

Abstract

Key Clinical Message Findings here imply lingering of virus, SARS‐CoV‐2, in the body for months. Thus, Nitazoxanide and/or other anti‐viral medications might be potential options to combat long COVID. This could transform treatment for long COVID patients globally. Abstract Long COVID or post‐acute sequelae of COVID‐19 (PASC) continues to affect many people even after a relatively mild acute illness. Underlying causes of PASC are poorly understood. There is no particular treatment or management program developed yet. Thus, the possibility of well‐known, safe anti‐viral medications use against PASC is proposed here.

Keywords

• acyclovir
• anti‐viral medication
• COVID‐19
• herpesviruses
• latent virus reactivation
• long COVID